VKH
ONCT

Virtu KCG Holdings’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Virtu KCG Holdings’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-24
Closed -$26K – 3897
2016
Q3 		$26K Buy
24
+16
+200% +$14K ﹤0.01% 2899
2016
Q2 		$6K Buy
+8
New +$7.48K ﹤0.01% 2873
2016
Q1 		– Sell
-16
Closed -$15K – 3828
2015
Q4 		$15K Buy
+16
New +$21.1K ﹤0.01% 3336
2015
Q3 		– Sell
-14
Closed -$28K – 3930
2015
Q2 		$28K Sell
14
-13
-48% -$18.5K ﹤0.01% 3157
2015
Q1 		$26K Sell
27
-40
-60% -$39.8K ﹤0.01% 2923
2014
Q4 		$69K Buy
67
+35
+109% +$31.2K ﹤0.01% 3348
2014
Q3 		$32K Buy
32
+14
+78% +$20.6K ﹤0.01% 3418
2014
Q2 		$35K Sell
18
-22
-55% -$43.5K ﹤0.01% 3477
2014
Q1 		$84K Buy
40
+18
+82% +$44.8K ﹤0.01% 3248
2013
Q4 		$50K Buy
22
+10
+83% +$22.9K ﹤0.01% 3600
2013
Q3 		$33K Buy
+12
New +$59.7K ﹤0.01% 3563

Other funds holding ONCT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FHA
First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return

Virtu KCG Holdings's ONCT Position: Q4 2016 in Review

Virtu KCG Holdings sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2016, closing a stake of 24 shares — an estimated $26K sold.

Virtu KCG Holdings first reported a position in ONCT in Q3 2013 and held it in 11 quarters. The position peaked at $84K in Q1 2014. 21 funds tracked by Wall St. Rank hold ONCT as of Q4 2016.

  • Virtu KCG Holdings reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 24 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $26K.
  • Virtu KCG Holdings first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2013 and held it in 11 quarters.
  • Virtu KCG Holdings's Oncternal Therapeutics, Inc. Common Stock position peaked at $84K in Q1 2014.
  • 21 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.